vs

Side-by-side financial comparison of IQVIA (IQV) and Xylem Inc. (XYL). Click either name above to swap in a different company.

IQVIA is the larger business by last-quarter revenue ($4.2B vs $2.1B, roughly 2.0× Xylem Inc.). Xylem Inc. runs the higher net margin — 8.9% vs 6.6%, a 2.3% gap on every dollar of revenue. On growth, IQVIA posted the faster year-over-year revenue change (8.4% vs 2.7%). Over the past eight quarters, IQVIA's revenue compounded faster (4.3% CAGR vs -1.0%).

IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research.

Xylem is one of the two types of transport tissue in vascular plants, the other being phloem; both of these are part of the vascular bundle. The basic function of the xylem is to transport water upward from the roots to parts of the plants such as stems and leaves, but it also transports nutrients. The word xylem is derived from the Ancient Greek word ξύλον (xúlon), meaning "wood"; the best-known xylem tissue is wood, though it is found throughout a plant.

IQV vs XYL — Head-to-Head

Bigger by revenue
IQV
IQV
2.0× larger
IQV
$4.2B
$2.1B
XYL
Growing faster (revenue YoY)
IQV
IQV
+5.7% gap
IQV
8.4%
2.7%
XYL
Higher net margin
XYL
XYL
2.3% more per $
XYL
8.9%
6.6%
IQV
Faster 2-yr revenue CAGR
IQV
IQV
Annualised
IQV
4.3%
-1.0%
XYL

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
IQV
IQV
XYL
XYL
Revenue
$4.2B
$2.1B
Net Profit
$275.0M
$189.0M
Gross Margin
37.8%
Operating Margin
12.4%
11.5%
Net Margin
6.6%
8.9%
Revenue YoY
8.4%
2.7%
Net Profit YoY
10.0%
100.0%
EPS (diluted)
$1.61
$0.79

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IQV
IQV
XYL
XYL
Q1 26
$4.2B
$2.1B
Q4 25
$4.4B
$2.4B
Q3 25
$4.1B
$2.3B
Q2 25
$4.0B
$2.3B
Q1 25
$3.8B
$2.1B
Q4 24
$4.0B
$2.3B
Q3 24
$3.9B
$2.1B
Q2 24
$3.8B
$2.2B
Net Profit
IQV
IQV
XYL
XYL
Q1 26
$275.0M
$189.0M
Q4 25
$514.0M
$335.0M
Q3 25
$331.0M
$227.0M
Q2 25
$266.0M
$226.0M
Q1 25
$249.0M
$169.0M
Q4 24
$437.0M
$326.0M
Q3 24
$285.0M
$217.0M
Q2 24
$363.0M
$194.0M
Gross Margin
IQV
IQV
XYL
XYL
Q1 26
37.8%
Q4 25
38.9%
Q3 25
38.9%
Q2 25
38.8%
Q1 25
37.1%
Q4 24
38.0%
Q3 24
23.5%
37.3%
Q2 24
22.6%
37.8%
Operating Margin
IQV
IQV
XYL
XYL
Q1 26
12.4%
11.5%
Q4 25
14.4%
14.7%
Q3 25
13.5%
14.7%
Q2 25
12.6%
13.3%
Q1 25
13.0%
11.2%
Q4 24
15.8%
11.8%
Q3 24
14.1%
13.3%
Q2 24
13.6%
11.7%
Net Margin
IQV
IQV
XYL
XYL
Q1 26
6.6%
8.9%
Q4 25
11.8%
14.0%
Q3 25
8.1%
10.0%
Q2 25
6.6%
9.8%
Q1 25
6.5%
8.2%
Q4 24
11.0%
14.5%
Q3 24
7.3%
10.3%
Q2 24
9.5%
8.9%
EPS (diluted)
IQV
IQV
XYL
XYL
Q1 26
$1.61
$0.79
Q4 25
$2.97
$1.37
Q3 25
$1.93
$0.93
Q2 25
$1.54
$0.93
Q1 25
$1.40
$0.69
Q4 24
$2.41
$1.33
Q3 24
$1.55
$0.89
Q2 24
$1.97
$0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IQV
IQV
XYL
XYL
Cash + ST InvestmentsLiquidity on hand
$1.9B
$808.0M
Total DebtLower is stronger
$15.8B
$1.9B
Stockholders' EquityBook value
$6.3B
$11.0B
Total Assets
$29.7B
$17.0B
Debt / EquityLower = less leverage
2.49×
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IQV
IQV
XYL
XYL
Q1 26
$1.9B
$808.0M
Q4 25
$2.1B
$1.5B
Q3 25
$2.0B
$1.2B
Q2 25
$2.2B
$1.2B
Q1 25
$1.9B
$1.1B
Q4 24
$1.8B
$1.1B
Q3 24
$1.7B
$989.0M
Q2 24
$1.7B
$815.0M
Total Debt
IQV
IQV
XYL
XYL
Q1 26
$15.8B
$1.9B
Q4 25
$2.0B
Q3 25
$2.0B
Q2 25
$2.0B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
Q2 24
Stockholders' Equity
IQV
IQV
XYL
XYL
Q1 26
$6.3B
$11.0B
Q4 25
$6.5B
$11.5B
Q3 25
$6.2B
$11.2B
Q2 25
$5.8B
$11.1B
Q1 25
$6.0B
$10.8B
Q4 24
$6.1B
$10.6B
Q3 24
$7.0B
$10.6B
Q2 24
$6.7B
$10.3B
Total Assets
IQV
IQV
XYL
XYL
Q1 26
$29.7B
$17.0B
Q4 25
$29.9B
$17.6B
Q3 25
$28.7B
$17.3B
Q2 25
$28.6B
$17.2B
Q1 25
$27.3B
$16.6B
Q4 24
$26.9B
$16.5B
Q3 24
$27.2B
$16.0B
Q2 24
$26.4B
$15.8B
Debt / Equity
IQV
IQV
XYL
XYL
Q1 26
2.49×
0.18×
Q4 25
0.17×
Q3 25
0.18×
Q2 25
0.18×
Q1 25
0.19×
Q4 24
0.19×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IQV
IQV
XYL
XYL
Operating Cash FlowLast quarter
$618.0M
Free Cash FlowOCF − Capex
$491.0M
FCF MarginFCF / Revenue
11.8%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
2.25×
TTM Free Cash FlowTrailing 4 quarters
$2.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IQV
IQV
XYL
XYL
Q1 26
$618.0M
Q4 25
$735.0M
$543.0M
Q3 25
$908.0M
$360.0M
Q2 25
$443.0M
$305.0M
Q1 25
$568.0M
$33.0M
Q4 24
$885.0M
$575.0M
Q3 24
$721.0M
$311.0M
Q2 24
$588.0M
$288.0M
Free Cash Flow
IQV
IQV
XYL
XYL
Q1 26
$491.0M
Q4 25
$561.0M
$460.0M
Q3 25
$772.0M
$281.0M
Q2 25
$292.0M
$207.0M
Q1 25
$426.0M
$-38.0M
Q4 24
$721.0M
$475.0M
Q3 24
$571.0M
$237.0M
Q2 24
$445.0M
$215.0M
FCF Margin
IQV
IQV
XYL
XYL
Q1 26
11.8%
Q4 25
12.9%
19.2%
Q3 25
18.8%
12.4%
Q2 25
7.3%
9.0%
Q1 25
11.1%
-1.8%
Q4 24
18.2%
21.1%
Q3 24
14.7%
11.3%
Q2 24
11.7%
9.9%
Capex Intensity
IQV
IQV
XYL
XYL
Q1 26
4.2%
Q4 25
4.0%
3.5%
Q3 25
3.3%
3.5%
Q2 25
3.8%
4.3%
Q1 25
3.7%
3.4%
Q4 24
4.1%
4.4%
Q3 24
3.9%
3.5%
Q2 24
3.7%
3.4%
Cash Conversion
IQV
IQV
XYL
XYL
Q1 26
2.25×
Q4 25
1.43×
1.62×
Q3 25
2.74×
1.59×
Q2 25
1.67×
1.35×
Q1 25
2.28×
0.20×
Q4 24
2.03×
1.76×
Q3 24
2.53×
1.43×
Q2 24
1.62×
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IQV
IQV

Segment breakdown not available.

XYL
XYL

Revenue from products$1.8B83%
Revenue from services$368.0M17%

Related Comparisons